PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2013.2662014473424-435Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNTJames Chin-Hsin Yang, Myung-Ju Ahn, Kazuhiko Nakagawa, Tomohide Tamura, Helen Barraclough, Sotaro Enatsu, Rebecca Cheng, Mauro Orlandohttp://e-crt.org/upload/pdf/crt-2013-266.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2013.266, http://www.e-crt.org/upload/pdf/crt-2013-266.pdf
Annals of Oncology10.1093/annonc/mdw383.82201627vi445A cross-trial comparison of pemetrexed-platinum followed by pemetrexed continuation maintenance versus gemcitabine-cisplatin without maintenance in chemotherapy-naive patients with advanced nonsquamous non-small-cell lung cancerY.-L. Wu, B. Zhang, X. Wang, M. Orlando, H. Chihttps://api.elsevier.com/content/article/PII:S0923753419449053?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419449053?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/27/suppl_6/1282P/19451618/mdw383.82.pdf
Clinical Lung Cancer10.1016/j.cllc.2018.05.0132018196e823-e830Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of CareJyoti D. Patel, Luis Paz-Ares, Ralph G. Zinner, Fabrice Barlesi, Andrew G. Koustenis, Coleman K. Obasajuhttps://api.elsevier.com/content/article/PII:S1525730418301335?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730418301335?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2014.07.0052014853408-414Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsG.V. Scagliotti, C. Gridelli, F. de Marinis, M. Thomas, M. Dediu, J.-L. Pujol, C. Manegold, B. San Antonio, P.M. Peterson, W. John, N. Chouaki, C. Visseren-Grul, L.G. Paz-Areshttps://api.elsevier.com/content/article/PII:S0169500214003055?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500214003055?httpAccept=text/plain
Clinical Lung Cancer10.3816/clc.2010.n.0452010115352-357Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous HistologyRalph G. Zinner, Scott B. Saxman, Guangbin Peng, Matthew J. Monberg, Waldo I. Ortuzarhttps://api.elsevier.com/content/article/PII:S1525730411700705?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411700705?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2011.12.0022012135340-346Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non–Small-Cell Lung CancerCesare Gridelli, Thomas Brodowicz, Corey J. Langer, Patrick Peterson, Mominul Islam, Susan C. Guba, Patti Moore, Carla M. Visseren-Grul, Giorgio Scagliottihttps://api.elsevier.com/content/article/PII:S1525730411003019?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730411003019?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2015.01.0012015166e131-e140Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung CancerChung-Yu Chen, Jou-Wei Lin, Jenq-Wen Huang, Kuan-Yu Chen, Jin-Yuan Shih, Chong-Jen Yu, Pan-Chyr Yanghttps://api.elsevier.com/content/article/PII:S1525730415000042?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730415000042?httpAccept=text/plain
Chest10.1016/j.chest.2019.08.150220191564A1716THE RISK OF TREATMENT WITH PEMETREXED PLUS PLATINUM FOLLOWED BY MAINTENANCE WITH PEMETREXED FOR PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER CONCURRENT WITH INTERSTITIAL LUNG DISEASETetsuo Fujita, TSUGUKO KUROKI, YUKA SHIRAISHI, Hiroyuki Amano, makoto nakamura, Satoshi Hirano, Hiroshi Tabeta, SUKEYUKI NAKAMURAhttps://api.elsevier.com/content/article/PII:S0012369219330004?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0012369219330004?httpAccept=text/plain
Clinical Therapeutics10.1016/j.clinthera.2012.12.013201335154-65Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care SystemXiaohui Zeng, Liubao Peng, Jianhe Li, Gannong Chen, Chongqing Tan, Siying Wang, Xiaomin Wan, Lihui Ouyang, Ziying Zhaohttps://api.elsevier.com/content/article/PII:S0149291812007254?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291812007254?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2020.11.018202115125-29Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBLEdward B. Garon, Jong Seok Kim, Ramaswamy Govindanhttps://api.elsevier.com/content/article/PII:S0169500220306930?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220306930?httpAccept=text/plain